These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 12854088)

  • 1. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.
    Walsh TJ; Petraitis V; Petraitiene R; Field-Ridley A; Sutton D; Ghannoum M; Sein T; Schaufele R; Peter J; Bacher J; Casler H; Armstrong D; Espinel-Ingroff A; Rinaldi MG; Lyman CA
    J Infect Dis; 2003 Jul; 188(2):305-19. PubMed ID: 12854088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
    Warn PA; Morrissey G; Morrissey J; Denning DW
    J Antimicrob Chemother; 2003 Apr; 51(4):913-9. PubMed ID: 12654746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo resistance of a laboratory-selected Aspergillus fumigatus isolate to amphotericin B.
    Manavathu EK; Cutright JL; Chandrasekar PH
    Antimicrob Agents Chemother; 2005 Jan; 49(1):428-30. PubMed ID: 15616327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli.
    Lionakis MS; Lewis RE; Torres HA; Albert ND; Raad II; Kontoyiannis DP
    Diagn Microbiol Infect Dis; 2005 May; 52(1):15-20. PubMed ID: 15878437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activities of amphotericin B and AmBisome against Aspergillus isolates recovered from Italian patients treated for haematological malignancies.
    Colozza C; Posteraro B; Santilli S; De Carolis E; Sanguinetti M; Girmenia C
    Int J Antimicrob Agents; 2012 May; 39(5):440-3. PubMed ID: 22429723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
    Kaya AD; Kiraz N
    Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of high loading doses of liposomal amphotericin B in the treatment of experimental invasive pulmonary aspergillosis.
    Gavaldà J; Martín T; López P; Gomis X; Ramírez JL; Rodríguez D; Len O; Puigfel Y; Ruiz I; Pahissa A
    Clin Microbiol Infect; 2005 Dec; 11(12):999-1004. PubMed ID: 16307554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.
    Lewis RE; Liao G; Hou J; Chamilos G; Prince RA; Kontoyiannis DP
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1253-8. PubMed ID: 17261624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrinsic in vitro susceptibility of primary clinical isolates of Aspergillus fumigatus, Aspergillus terreus, Aspergillus nidulans, Candida albicans and Candida lusitaniae against amphotericin B.
    Singh J; Rimek D; Kappe R
    Mycoses; 2006 Mar; 49(2):96-103. PubMed ID: 16466441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antifungal resistance in Aspergillus terreus: A current scenario.
    Vahedi Shahandashti R; Lass-Flörl C
    Fungal Genet Biol; 2019 Oct; 131():103247. PubMed ID: 31247322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of antifungal agents and human monocytes on in vitro galactomannan release by Aspergillus spp. in liquid culture medium.
    Winn RM; Warris A; Gaustad P; Abrahamsen TG
    APMIS; 2007 Dec; 115(12):1364-9. PubMed ID: 18184406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies.
    Hachem RY; Kontoyiannis DP; Boktour MR; Afif C; Cooksley C; Bodey GP; Chatzinikolaou I; Perego C; Kantarjian HM; Raad II
    Cancer; 2004 Oct; 101(7):1594-600. PubMed ID: 15378491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential basis for amphotericin B resistance in Aspergillus terreus.
    Blum G; Perkhofer S; Haas H; Schrettl M; Würzner R; Dierich MP; Lass-Flörl C
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1553-5. PubMed ID: 18268082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blocking Hsp70 enhances the efficiency of amphotericin B treatment against resistant Aspergillus terreus strains.
    Blatzer M; Blum G; Jukic E; Posch W; Gruber P; Nagl M; Binder U; Maurer E; Sarg B; Lindner H; Lass-Flörl C; Wilflingseder D
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3778-88. PubMed ID: 25870060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose induction liposomal amphotericin B followed by de-escalation is effective in experimental Aspergillus terreus pneumonia.
    Lewis RE; Albert NP; Liao G; Wang W; Prince RA; Kontoyiannis DP
    J Antimicrob Chemother; 2013 May; 68(5):1148-51. PubMed ID: 23349440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp.
    Martín-Mazuelos E; Pemán J; Valverde A; Chaves M; Serrano MC; Cantón E
    J Antimicrob Chemother; 2003 Sep; 52(3):365-70. PubMed ID: 12917236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience.
    Lass-Flörl C; Griff K; Mayr A; Petzer A; Gastl G; Bonatti H; Freund M; Kropshofer G; Dierich MP; Nachbaur D
    Br J Haematol; 2005 Oct; 131(2):201-7. PubMed ID: 16197450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.
    Petraitiene R; Petraitis V; Groll AH; Sein T; Piscitelli S; Candelario M; Field-Ridley A; Avila N; Bacher J; Walsh TJ
    Antimicrob Agents Chemother; 2001 Mar; 45(3):857-69. PubMed ID: 11181372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New insight into amphotericin B resistance in Aspergillus terreus.
    Blum G; Hörtnagl C; Jukic E; Erbeznik T; Pümpel T; Dietrich H; Nagl M; Speth C; Rambach G; Lass-Flörl C
    Antimicrob Agents Chemother; 2013 Apr; 57(4):1583-8. PubMed ID: 23318794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First case of breakthrough pulmonary Aspergillus niveus infection in a patient after allogeneic hematopoietic stem cell transplantation.
    Auberger J; Lass-Flörl C; Clausen J; Bellmann R; Buzina W; Gastl G; Nachbaur D
    Diagn Microbiol Infect Dis; 2008 Nov; 62(3):336-9. PubMed ID: 18687556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.